New technologies delivered to your inbox Subscribe
The MIT Technology Licenses Office welcomes companies to get to know us personally. We find it most effective to work individually with a company to identify specific areas of interest. We then bring inventions, which specifically match the company's interests to the attention of the company. With 500 new invention disclosures coming into our office each year, our portfolio is constantly changing. The technologies highlighted here do not encompass our entire portfolio. We therefore encourage companies to keep in touch on a regular basis and also to contact us when a particular technology need arises.
Our technology is usually early stage and often requires substantial development by the licensing company before a commercial product is ready for market. Because of this, we often find that the best contact person from the company is one who is knowledgeable about the company's science and technology and also familiar with the long-term strategic plans of the company.
18076 – This invention reduces dosages and improves efficacy of RNA interference drugs including cancer therapeutics. Short interfering RNAs (siRNAs) have great therapeutic potential but clinical translation has been hindered by poor in vivo stability, low loading efficiency, and dose-limiting toxicity. The generation of periodic short hairpin RNA (concatemeric siRNA) via rolling circle... Read More
18507 – This invention is a bone reduction forcep. Existing bone reduction forceps, used in over 200,000 hand surgeries annually, do not allow sufficiently fine adjustment of the clamping force resulting in longer, more difficult procedures, increasing the risk of further bone breaking, anesthesia complications, misunion, or nonunion. This invention is a forcep design that allows both... Read More
15862 – This invention promotes repair of damaged bone and bone tissue without the need for auto or synthetic grafts for improved defect healing. Bone and bone tissue can only self-regenerate when the damage or defect is small, less than ~8mm. Larger defects require intervention to heal, and conventional treatment options are susceptible to failure due to the low rate of defect closure or... Read More
14511 – This invention facilitates the engineering of DNA constructs with an improved assembly technique. While there have been major advances in the field of DNA assembly the process still requires laborious and time consuming recombinant cloning. It takes several days to combine just two DNA parts into a new construct, and biological systems composed of many genes may only be realized... Read More
14321 – This invention may be applied to the targeted destruction of cancer cells. Current cancer treatments utilize a non-specific approach which inflicts damage on heathy tissue during the process of killing cancer cells. In addition, this general approach often requires multiple treatments causing further damage to healthy cells. This invention uses a RNAi-enhanced genetic logic... Read More
14044 – This invention is a reconfigurable chassis that allows for rapid construction and optimization of biocircuits. Technologies for cloning and recombination of genetic material are time-consuming and rate-limiting. For instance, transformed plasmids are less stable than chromosomal DNA and are limited in the number of different plasmids with which they can be co-transformed.... Read More
17190 – Lubricant-Impregnated Surfaces (LISs) can be used in a variety of applications from batteries to capacitor fabrication. For example, in flow batteries, controlled flow of the electrolyte and friction along the cell walls is very important. Introducing an LIS in this system increases controllability of electrolyte flow by minimizing the friction. Controlling flow and slipperiness... Read More
16742 – This invention diagnoses kinase inhibitor resistant cancer and also decreases resistance to kinase inhibitors for improved cancer treatments. Molecular-targeted cancer therapeutics eventually fail due to cancer’s ability to become resistant to drugs. How carcinogenic cells achieve this resistance is poorly understood, with genetic and gene expression changes accounting for only... Read More
15754 – This invention is a buccal drug delivery platform which topically targets oral cancer cells in the mouth for improved treatment of oral cancer. While the prevalence of many cancers is decreasing, the incidence of oral cancer (OC) has been increasing with over 640,000 cases diagnosed annually. Despite the fact that OC treatment is incredibly expensive with an annual cost of care of... Read More
14020 – This invention is a method to sense and destroy specific pathogens without the use of antimicrobial drugs. Nearly 2 million people die annually from water borne illnesses. Children in developing nations are most susceptible to these diseases which are becoming increasingly resistant to drugs. This invention is a versatile and effective cellular “sense-and-destroy” system capable... Read More